Company intelligence / Profile preview

Eros

Boston, Massachusetts, United Stateslifebiosciences.com ↗

Ownership: Private
Development stage: Other

Overview

Eros Therapeutics was a biotechnology company focused on developing novel therapies for skin health and aging-related dermatological conditions. As a subsidiary of Life Biosciences, the company primarily targeted the Transient Receptor Potential Vanilloid 3 (TRPV3) ion channel to treat moderate-to-severe psoriasis and atopic dermatitis. Its research aimed to leverage small molecule inhibitors to modulate skin barrier function and inflammatory responses. Following a strategic consolidation by its parent company, Eros Therapeutics' programs were integrated into the broader Life Biosciences portfolio to streamline longevity-focused research.

Therapeutic areas: Dermatology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Eros.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eros.

Explore the full profile